July 19, 2024

Rising prevalence of PCOS to boost growth of the PCOS diagnostic Market

The global PCOS diagnostic Market is estimated to be valued at US$ 710.0 Mn in 2023 and is expected to exhibit a CAGR of 5.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
The PCOS diagnostic market involves diagnosis of polycystic ovary syndrome (PCOS) which is a common reproductive and endocrinological disorder. PCOS is diagnosed majorly through ultrasound examination looking for polycystic ovaries and blood tests measuring reproductive and thyroid hormones. More recently, specific anti-Müllerian hormone (AMH) blood tests have also gained popularity for detecting PCOS. Early diagnosis plays a vital role in managing PCOS symptoms through lifestyle changes and medication to prevent long term health complications like diabetes, heart disease and endometrial cancer.

Market key trends:
One of the key trends in the PCOS diagnostic market is the increasing popularity of anti-Müllerian hormone (AMH) blood test. AMH levels are found to be higher in women with PCOS and it is a reliable biochemical marker for estimating ovarian reserve and polycystic ovaries. As AMH testing is non-invasive, painless and more convenient compared to ultrasound, its demand is growing significantly. Another major trend is the development of new diagnostic biomarkers and tools for early and accurate PCOS diagnosis. Various companies are conducting research on novel biomarkers like micro-RNAs and metabolomics profiling to improve PCOS management. Advancements in ultrasound technologies are also allowing detailed ovarian imaging for comprehensive diagnosis.
Porter’s Analysis
Threat of new entrants: The threat of new entrants in the PCOS diagnostic market is low as it requires high R&D investments and regulatory approvals to enter this market. Bargaining power of buyers: The bargaining power of buyers is moderate as there are many diagnostic tests and prescription drugs options available for PCOS treatment. Bargaining power of suppliers: The bargaining power of suppliers is low owing to the presence of many suppliers for raw materials in this market. Threat of new substitutes: The threat of new substitutes is low because currently there are limited substitutes for diagnostic tests available to detect PCOS. Competitive rivalry: High.

Key Takeaways
The global PCOS diagnostic market is expected to witness high growth, exhibiting CAGR of 5.3% over the forecast period, 2023 to 2030, due to increasing awareness regarding PCOS diagnostic tests.

The North America region currently dominates the global PCOS diagnostic market. Increasing incidence of PCOS and rising awareness about early diagnosis are fueling the growth of this regional market. The Asia Pacific region is expected to witness fastest growth during the forecast period owing to rising healthcare expenditure and growing women population in countries like China and India.

Key players operating in the PCOS diagnostic market are AbbVie, Novartis AG, Bausch Health Companies Inc., Galapagos NV, EyePoint Pharmaceuticals, Inc., Clearside Biomedical, Tarsier Pharma Ltd, Santen Pharmaceutical Co., Ltd., Bausch & Lomb Incorporated, Sanofi, Regeneron Pharmaceuticals, and Inc., Alimera Sciences. Key players are focusing on new product launches and geographical expansion to strengthen their market position.